TODD SUDIK: Open Payments
NPI 1710517560 · DU BOIS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,263 in 157 payments from 20 companies in 2025. Trend: 2023 $2,657 · 2024 $2,722 · 2025 $3,263
Food & beverage: $3,049Education: $214
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 45 | $993 |
| GlaxoSmithKline, LLC. | 45 | $653 |
| GENZYME CORPORATION | 18 | $550 |
| Regeneron Healthcare Solutions, Inc. | 12 | $143 |
| Actelion Pharmaceuticals US, Inc. | 3 | $130 |
| Insmed, Inc. | 4 | $105 |
| Electromed, Inc. | 5 | $96 |
| Verona Pharma, Inc. | 4 | $85 |
| SANOFI-AVENTIS U.S. LLC | 1 | $79 |
| Amgen Inc. | 4 | $78 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, BREZTRI, FASENRA, AIRSUPRA, TRELEGY ELLIPTA, OPSUMIT.
Industry payments across PA — which companies pay providers there.
